NCT05015894View on ClinicalTrials.gov

A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

August 2, 2022

Study Completion Date

August 2, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

NNC0480-0389

"A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days"

Trial Locations (1)

10117

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY